Next Article in Journal
Endogenous Matrix-Derived Inhibitors of Angiogenesis
Previous Article in Journal
The Use of Antiepileptic Drugs (AEDs) for the Treatment of Pediatric Aggression and Mood Disorders
Previous Article in Special Issue
Pharmacogenetics of Anti-Diabetes Drugs
Pharmaceuticals 2010, 3(9), 3005-3020; doi:10.3390/ph3093005
Review

Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action

,
,
,
 and *
Received: 29 July 2010; in revised form: 3 September 2010 / Accepted: 6 September 2010 / Published: 15 September 2010
(This article belongs to the Special Issue Antidiabetic Drugs)
View Full-Text   |   Download PDF [165 KB, uploaded 15 September 2010]
Abstract: Type 2 diabetes is a syndrome characterized by relative insulin deficiency, insulin resistance and increased hepatic glucose output. Medications used to treat the disease are designed to correct one or more of these metabolic abnormalities. Current recommendations of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) include diet and exercise as first-line therapy plus hypoglycemic drugs. Actually there are seven distinct classes of anti-hyperglicemic agents, each of them displaying unique pharmacologic properties. The aim of this review is to describe the pathophysiological basis of their mechanism of action, a necessary step to individualize treatment of diabetic people, taking into proper consideration potential benefits and secondary effects of drugs.
Keywords: hypoglycemic drugs; sulfonylureas; thiazolidinediones; incretin mimeticshypoglycemic drugs; sulfonylureas; thiazolidinediones; incretin mimetics hypoglycemic drugs; sulfonylureas; thiazolidinediones; incretin mimeticshypoglycemic drugs; sulfonylureas; thiazolidinediones; incretin mimetics
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Lorenzati, B.; Zucco, C.; Miglietta, S.; Lamberti, F.; Bruno, G. Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. Pharmaceuticals 2010, 3, 3005-3020.

AMA Style

Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G. Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. Pharmaceuticals. 2010; 3(9):3005-3020.

Chicago/Turabian Style

Lorenzati, Bartolomeo; Zucco, Chiara; Miglietta, Sara; Lamberti, Federico; Bruno, Graziella. 2010. "Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action." Pharmaceuticals 3, no. 9: 3005-3020.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert